Many physicians are not telling cancer patients about the cardiotoxicity risks of treatments and may not be fully aware of the dangers themselves. A new study reveals an urgent need to look after the hearts of these patients. The research is presented today at EuroHeartCare 2019, a scientific congress of the European Society of Cardiology (ESC).
* This article was originally published here
Sunday, 5 May 2019
Study reveals reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy
A team of researchers affiliated with Johns Hopkins University and Memorial Sloan Kettering Cancer Center has found some of the reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy in cancer patients. In their paper published in the journal Science, the group describes their study of the therapy using mouse models, and what they found.
* This article was originally published here
* This article was originally published here
Subscribe to:
Posts (Atom)